E-HEALTH - E-SANTE - PHARMAGEEK
287.1K views | +42 today
Follow

Diabetes: More than a word, much more than a diagnosis

From www.kevinmd.com

As a family doctor based in Brooklyn, New York, who has served the needs of my community since completing residency in 1982, I find myself with a unique privilege and opportunity to observe disease and wellness, the effects of lifestyle, policy and the collective efforts of myself and others, as we attempt to keep our patients well and affect the statistical bottom line. I’m typing this as I also think about the more than 10% of diabetics who are listed in my practice. A prime example of a need for population management if there ever was one.


Given my large population of diabetes patients and years, upon years of experience diagnosing and treating this disease, I wanted to share my story and approach to managing this population.


While there has been some improvement due to total team effort between my staff, insurance company reminders, patient education and incentives to patients, still greater than 50% remained uncontrolled with A1c levels greater than 7.0% and 20% with A1c levels greater than 10.0%. Tragically, we have had patients that have lost sight, limbs and kidneys in the last year to uncontrolled diabetes, Every cardiovascular complication has been manifest in one way or the other.


Read more at: http://www.kevinmd.com/blog/2013/11/diabetes-word-diagnosis.html

No comment yet.

New mHealth Projects Make Waves in Diabetes Management

From healthworkscollective.com

Biomedtrics, a Pleasanton, Calif.-based technology company, has unveiled a Bluetooth device that integrates with a wide variety of blood glucose meters and automatically transmits readings to s secure website.

No comment yet.

Sanofi debuts new insulin tools

From www.mmm-online.com

The new tools aim to help patients and providers better track blood glucose levels and administer insulin.
No comment yet.

CyberDoctor takes new angle on medication adherence

From mobihealthnews.com

A patient-facing app from CyberDoctor is taking a new approach to addressing the $290 billion a year problem of medication adherence.
No comment yet.

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

From www.nejm.org

During the United Kingdom Prospective Diabetes Study (UKPDS), patients with type 2 diabetes mellitus who received intensive glucose therapy had a lower risk of microvascular complications than did those receiving conventional dietary therapy. We conducted post-trial monitoring to determine whether this improved glucose control persisted and whether such therapy had a long-term effect on macrovascular outcomes.

Results Between-group differences in glycated hemoglobin levels were lost after the first year. In the sulfonylurea–insulin group, relative reductions in risk persisted at 10 years for any diabetes-related end point (9%, P=0.04) and microvascular disease (24%, P=0.001), and risk reductions for myocardial infarction (15%, P=0.01) and death from any cause (13%, P=0.007) emerged over time, as more events occurred. In the metformin group, significant risk reductions persisted for any diabetes-related end point (21%, P=0.01), myocardial infarction (33%, P=0.005), and death from any cause (27%, P=0.002).

Conclusions

Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up. A continued benefit after metformin therapy was evident among overweight patients. (UKPDS 80; Current Controlled Trials number.

Seth Bilazarian, MD's curator insight, October 8, 2013 9:36 AM

Amazing! Twenty five years ago the UKPDS published the follow-up of metformin in diabetes showing a benefit on heart attack and death even years after patients came off the drug.  Despite years of basic science and clinical research and billions of dollars spent on development of new therapies we still don't have a single other diabetes drug that reduces heart attack risk. Many drugs have been developed for blood sugar control but all have shown no benefit over placebo for reduction of heart attack risk for diabetics.  Only metformin.

Diabetics Encouraged to Use New Social Media Platform Gluco-Share

From mhealthwatch.com

In the fight against diabetes, King’s Variety Stores – simply known as “King’s” in the company’s home state of Idaho -  has joined forces with the Madden Family in the launch of the new app Gluco-Share.
No comment yet.

New game app improves adherence among diabetes patients, study finds | Drug Store News

From drugstorenews.com

SANTA CLARA, Calif. — A new mobile game app designed by CyberDoctor showed improvements in medication adherence, diet and exercise in diabetes patients, according to a study. The company said that breakthrough clinical trial results for the game, called PatientPartner," documented for the first time the effectiveness of a story-driven game in changing health behavior and biomarkers. The study was conducted among 100 nonadherence patients at Hershey, Pa.-based Pinnacle Health Systems and presented at the Health2.0 Conference Wednesday in Santa Clara, Calif. According to the study, medication adherence among patients using the game increased from 58% to 95%, equivalent to three additional days of adherence per week. Meanwhile, diet and exercise adherence respectively increased by 24% and 14%, all contributing to a decrease in blood sugar levels from 10.7% to 9.7%.

No comment yet.

Use of Electronic Health Records among Patients with Diabetes

From www.diabetesincontrol.com

Diabetes In Control is a free weekly diabetes newsletter dedicated to helping medical professionals in diabetes care better help their diabetes patients.
No comment yet.